Simulation of the Effect of P-glycoprotein on Drug Absorption in the Human Gastrointestinal Tract

Author(s): S. Neuhoff, J. Yang, M. Jamei, G. T. Tucker, A. Rostami-Hodjegan
Year:

Simulation of Virtual Human Subjects to Investigate the Impact of CYP2C19*17/*17 on Omeprazole Exposure

Author(s): L. M. Almond, K. Abduljalil, K. Rowland-Yeo, A. Rostami-Hodjegan
Year:

Predicting the Developmental PK/PD of Cyclosporine (CsA) in Pediatrics

Author(s): K. Abduljalil, T. N. Johnson, M. Jamei, D. Edwards, A. Rostami-Hodjegan
Year:

Prediction of Tolerance to Caffeine Pressor Effect during Pregnancy using Physiologically-based PK/PD Modeling

Author(s): K. Abduljalil, R. Rose, T. N. Johnson, T. Cain, L. Gaohua, D. Edwards, M. Jamei, A. Rostami-Hodjegan
Year:

Population Pharmacokinetics Define Dosing Recommendations of Oseltamivir in Neonates and Infants with Influenza

Author(s): Mohamed Kamal, Edward Acosta, David Kimberlin, Leonid Gibiansky, Penelope Jester, Vis Niranjan, Barbara Rath, Barry Clinch, Pablo Sanchez, Krow Ampofo, Richard Whitley, Craig Rayner
Year:

Exposure–Response Relationship of Cenicriviroc with Week 24 Virologic Outcomes in Treatment-naïve HIV-1-infected Adults with CCR5-tropic Virus

Author(s): E. Lefebvre, J. Enejosa, Martin Béliveau, Claudia Jomphe, Jean-Francois Marier, Craig Rayner, Patrick Smith, J. Gathe
Year:

The Australian Medical Countermeasures Consortium and Medical Countermeasures Products Australia (MCPA)

Author(s): Felicia Pradera, David Lester, Leigh Farrell, John Lowenthal, Martyn Jeggo, Simon Tucker, Helen Fisher, Craig Rayner
Year:

Estimating Health Outcomes of Antiviral Use in Influenza Outbreaks by Linking PK/PD and Epidemiology via a Transmission Dynamic Model: A Novel Approach

Author(s): Patrick Smith, C. Kirkpatrick, Craig Rayner, Keith Nieforth, Georgina Dall, S. Toovey, D.C.M. Kong, D.B.C. Wu, N. Chaiyakunapruk, K.K.C. Lee, C. Pratoomsoot, H.Y. Chong, A. Kamauu, R.E. Nelson, M.A. Kamal 
Year:

Oseltamivir Use in an Influenza Outbreak: Linking Pharmacology to Pharmacoeconomics

Author(s): D.B.C. Wu, N. Chaiyakunapruk, C. Pratoomsoot, K.K.C. Lee, H.Y. Chong, R.E. Nelson, Patrick Smith, C. Kirkpatrick, M.A. Kamal, Keith Nieforth, Georgina Dall, S. Toovey, D.C.M. Kong, A. Kamauu, Craig Rayner
Year:

Raltegravir Dosing in Neonates (IMPAACT P1110): Use of Allometry and Maturation in PK Modeling to Develop a Daily Dosing Regimen for Investigation During the First Weeks of Life

Author(s): Jos Lommerse, Diana Clarke, Anne Chain, Han Witjes, Hedy Teppler, Edmund Capparelli, Edward Acosta, Matthew Rizk, Larissa Wenning, Thomas Kerbusch, Stephen Spector, Betsy Smith, Mark Mirochnick
Year:

Exploring the Hypothesis that Age-related Differences in the Response to Triazolam are Due to Altered Pharmacokinetics and Increased Sensitivity to the Drug in the Elderly

Author(s): Manoranjenni Chetty, Masoud Jamei, Amin Rostami-Hodjegan
Year:

Application of PBPK Modeling to Assess the Victim DDI Potential of Paclitaxel in Oncology Combination Therapies

Author(s): Alice Ke, Karen Rowland Yeo
Year:

Predicting the Impact of CYP3A5 Polymorphism on Tacrolimus Trough Concentrations in Black African Transplant Recipients

Author(s): Krishna Machavaram, Lisa Almond, Ben Small, Zoe Barter, Masoud Jamei, Amin Rostami-Hodjegan, Iain Gardner
Year:

Aripiprazole Lauroxil Pharmacokinetics: Application of Modeling and Simulation for Dosing Considerations of a Long-acting Injectable Antipsychotic in Persons with Schizophrenia

Author(s): Marjie Hard, Brian Sadler, Richard Mills, Karen Rowland Yeo, Ryan Turncliff, Leslie Citrome
Year:

Predicting the PK/PD of Ibuprofen in Children

Author(s): K. Abduljalil, E.P.M. Grist, T. N. Johnson, M. Jamei, D. Edwards, A. Rostami-Hodjegan
Year:

Prediction of human intestinal metabolism of CYP3A substrates using the Advanced, Dissolution, Absorption and Metabolism (ADAM) Model

Author(s): H. Mishra, M. Jamei, K. Rowland-Yeo, A. Rostami-Hodjegan
Year:

Assessment of the Induction of Systemic Clearance vs. First-Pass Metabolism of Midazolam by Rifampicin Using a Physiologically-based Dynamic Model

Author(s): L. M. Almond, K. Okialda, S. Mukadam, K. Rowland-Yeo, I. Gardner, A. Rostami-Hodjegan, J. R. Kenny
Year:

Utility of Data from Recombinant Expressed Genetic Variants of CYPs in Predicting the Influence of Genotype on In Vivo Drug Kinetics: The Case for S-Warfarin

Author(s): L. M. Almond, K. Rowland-Yeo, E. M. Howgate, G. T. Tucker, A. Rostami-Hodjegan
Year:

Prediction of the oral clearance of S-warfarin in CYP2C9 genotypes from in vitro enzyme kinetic data using in vitro enzyme kinetic data

Author(s): L. M. Almond, K. Rowland-Yeo, E. M. Howgate, G. T. Tucker, A. Rostami-Hodjegan
Year:

Prediction of the oral clearance of tolbutamide in individuals with different CYP2C9 genotypes using in vitro enzyme kinetic data

Author(s): L. M. Almond, K. Rowland-Yeo, G. L. Dickinson, E. M. Howgate, G. T. Tucker, A. Rostami-Hodjegan
Year:

Learn More LinkedIn